{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:56:36Z","timestamp":1790870196551,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20155-9","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:07:55Z","timestamp":1784290075000},"page":"9848-9856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of Axillary Surgical Management of Patients with Occult Breast Cancer with Axillary Metastasis"],"prefix":"10.1245","volume":"33","author":[{"given":"Saranya","family":"Prathibha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney N.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalliah M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3228","authenticated-orcid":false,"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"20155_CR1","doi-asserted-by":"crossref","unstructured":"Poulakaki T. Occult breast cancer. Breast Cancer Essentials. Springer, Cham; 2021.","DOI":"10.1007\/978-3-030-73147-2_59"},{"key":"20155_CR2","unstructured":"America. AACoRUSo. ACR Practice parameter for contrast-enhanced breast MRI, ACR: American College of Radiology. United States of America. https:\/\/coilink.org\/20.500.12592\/8w4qtb1 Retrieved on 27 Apr 2026."},{"issue":"2","key":"20155_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","volume":"36","author":"J de Bresser","year":"2010","unstructured":"de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36(2):114\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2009.09.007.","journal-title":"Eur J Surg Oncol."},{"issue":"17","key":"20155_CR4","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1002\/cncr.25197","volume":"116","author":"GV Walker","year":"2010","unstructured":"Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000\u20136. https:\/\/doi.org\/10.1002\/cncr.25197.","journal-title":"Cancer."},{"issue":"10","key":"20155_CR5","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","volume":"24","author":"LK Hessler","year":"2017","unstructured":"Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol. 2017;24(10):2907\u201314. https:\/\/doi.org\/10.1245\/s10434-017-5928-x.","journal-title":"Ann Surg Oncol."},{"key":"20155_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: occult primary (Cancer of Unknown Primary [CUP]). Version 1.2026. Accessed 04\/15\/2026, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/occult.pdf."},{"key":"20155_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed 04\/15\/2026, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"13","key":"20155_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryden L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390(13):1163\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Engl J Med."},{"key":"20155_CR9","doi-asserted-by":"publisher","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","DOI":"10.1016\/S1470-2045(14)70460-7"},{"issue":"6","key":"20155_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA."},{"issue":"9","key":"20155_CR11","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29(9):5732\u201344. https:\/\/doi.org\/10.1245\/s10434-022-11866-w.","journal-title":"Ann Surg Oncol."},{"issue":"14","key":"20155_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"7","key":"20155_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"issue":"3","key":"20155_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau J-F, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20155_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe J-M, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.\u00a0J Clin Oncol. 2009;27(5):726\u201332. https:\/\/doi.org\/10.1200\/JCO.2008.18.3228.","journal-title":"Multicenter Study. J Clin Oncol."},{"issue":"9","key":"20155_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"issue":"1","key":"20155_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.\u00a0Lancet Oncol. 2012;13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9.","journal-title":"Lancet Oncol."},{"issue":"9","key":"20155_CR18","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","volume":"31","author":"BE Palis","year":"2024","unstructured":"Palis BE, Janczewski LM, Browner AE, et al. The National Cancer Database conforms to the standardized framework for registry and data quality. Ann Surg Oncol. 2024;31(9):5546\u201359. https:\/\/doi.org\/10.1245\/s10434-024-15393-8.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20155_CR19","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1245\/s10434-020-08227-w","volume":"27","author":"BL Cohen","year":"2020","unstructured":"Cohen BL, Collier AL, Kelly KN, et al. Surgical management of the axilla in patients with occult breast cancer (cT0 N+) after neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(6):1830\u201341. https:\/\/doi.org\/10.1245\/s10434-020-08227-w.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20155_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10549-024-07500-w","volume":"209","author":"M LaBella","year":"2025","unstructured":"LaBella M, Lile-King RE, Agala CB, et al. Trends in management and related outcomes for occult primary breast cancer. Breast Cancer Res Treat. 2025;209(2):367\u201374. https:\/\/doi.org\/10.1007\/s10549-024-07500-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"20155_CR21","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1245\/s10434-025-19065-z","volume":"33","author":"CN Day","year":"2026","unstructured":"Day CN, Habermann EB, Boughey JC. Evolution of breast cancer treatment 2010\u20132023. Ann Surg Oncol. 2026;33(4):3244\u201353. https:\/\/doi.org\/10.1245\/s10434-025-19065-z.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"20155_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.24.01052","volume":"43","author":"G Montagna","year":"2025","unstructured":"Montagna G, Laws A, Ferrucci M, et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): The OPBC-05\/ICARO Study. J Clin Oncol. 2025;43(7):810\u201320. https:\/\/doi.org\/10.1200\/JCO.24.01052.","journal-title":"J Clin Oncol."},{"issue":"1","key":"20155_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","volume":"27","author":"G Montagna","year":"2026","unstructured":"Montagna G, Alvarado M, Myers S, et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): an international, retrospective cohort study. Lancet Oncol. 2026;27(1):57\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(25)00598-4.","journal-title":"Lancet Oncol."},{"issue":"5","key":"20155_CR24","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","volume":"32","author":"JC Boughey","year":"2025","unstructured":"Boughey JC, Yu H, Switalla K, et al. Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from > 1500 patients on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(5):3278\u201391. https:\/\/doi.org\/10.1245\/s10434-025-16973-y.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20155_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejso.2022.11.099","volume":"49","author":"Y Park","year":"2023","unstructured":"Park Y, Shin YS, Kim K, et al. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: a retrospective multicenter study (KROG 21\u201306). Eur J Surg Oncol. 2023;49(3):589\u201396. https:\/\/doi.org\/10.1016\/j.ejso.2022.11.099.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"20155_CR26","doi-asserted-by":"publisher","first-page":"e35610","DOI":"10.1002\/cncr.35610","volume":"131","author":"M Muslumanoglu","year":"2025","unstructured":"Muslumanoglu M, Cabioglu N, Igci A, et al. Combined analysis of the MF18-02\/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer. 2025;131(1):e35610. https:\/\/doi.org\/10.1002\/cncr.35610.","journal-title":"Cancer."},{"issue":"11","key":"20155_CR27","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","volume":"30","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Yu H, Dugan CL, et al. Changes in surgical management of the axilla over 11 years\u2014report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 Trial. Ann Surg Oncol. 2023;30(11):6401\u201310. https:\/\/doi.org\/10.1245\/s10434-023-13759-y.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"20155_CR28","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","volume":"31","author":"JN Limberg","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(13):8813\u201320. https:\/\/doi.org\/10.1245\/s10434-024-16143-6.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20155_CR29","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol. 2019;26(11):3517\u201325. https:\/\/doi.org\/10.1245\/s10434-019-07583-6.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20155_CR30","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1245\/s10434-019-07540-3","volume":"26","author":"MK Srour","year":"2019","unstructured":"Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a National Cancer Database (NCDB) Analysis. Ann Surg Oncol. 2019;26(10):3305\u201311. https:\/\/doi.org\/10.1245\/s10434-019-07540-3.","journal-title":"Ann Surg Oncol."},{"key":"20155_CR31","doi-asserted-by":"publisher","unstructured":"Prathibha S, Hoskin TL, Goetz M, J.C. B. 2026 Impact of advances in neoadjuvant chemotherapy on nodal pCR and axillary surgery. Ann Surg Oncol. 33(suppl 1):S20. https:\/\/doi.org\/10.1245\/s10434-026-19303-y.","DOI":"10.1245\/s10434-026-19303-y"},{"issue":"4","key":"20155_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy.\u00a0JAMA Oncol. 2016;2(4):508\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4935.","journal-title":"JAMA Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20155-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:17:23Z","timestamp":1790867843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20155"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20155-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Judy Boughey\u2014receives research funding paid to her institution from Eli Lilly, SimBioSys and Quantum Leap Healthcare. She is on the DSMB for Cairns Surgical; Dr Boughey is supported by the W.H. Odell Professorship in Individualized Medicine","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}